ClinicalTrials.gg
RecruitingNCT06868511NAS-TNKUpdated Apr 22, 2025

Neuronavigation-assisted Stereotactic Puncture With Tenecteplase for Acute Intracerebral Hemorrhage

A Phase 3 interventional study of Neuronavigation-assisted Stereotactic Minimally Invasive Puncture Combined with Tenecteplase and Standard medical treatment in Deep Intracerebral Hemorrhage (ICH), sponsored by Beijing Tiantan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-04-22.

Sponsored by Beijing Tiantan Hospital · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
732
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Cerebral Hemorrhage by Beijing Tiantan Hospital — 14 open to participants now, 15 under way, 3 of them phase 3. Cerebral Hemorrhage · Beijing Tiantan Hospital.

Planned enrollment
2nd of 15
732 · median 240
Started
2025
with 3 others
Phase 3
3 of 22
3 open now
Primary completion
2027-03
later than 5 of 14 live
Registered
14th of 22
by date

Among the 22 studies in Cerebral Hemorrhage by Beijing Tiantan Hospital, this one is the 2nd largest by planned enrollment of the 15 interventional ones that give a count, is one of 4 that started in 2025, is one of 3 in phase 3, reaches primary completion later than 5 of the 14 other live ones, and was the 14th registered.

Cerebral Hemorrhage

458 studies on the registry are indexed under Cerebral Hemorrhage; 173 are open to participants now.

Browse Cerebral Hemorrhage studies →

Open to participants now

14 of the 22 studies in Cerebral Hemorrhage by Beijing Tiantan Hospital are open now, in 1 country. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Where they have run

Who these studies take

Of the 115 Cerebral Hemorrhage studies recruiting now, 61 (53%) set no upper age limit and 9 (8%) stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Cerebral Hemorrhage by Beijing Tiantan Hospital, or all of them as a file.
02

Study summary

Background Minimally invasive puncture surgery followed by thrombolysis has been proven to be an effective approach for managing hypertensive intracerebral hemorrhage. Nevertheless, its impact on improving neurological outcomes remains controversial. The integration of neuronavigation-assisted stereotactic (NAS) technology will significantly help enhance the accuracy of catheter placement, while tenecteplase (TNK), a third-generation thrombolytic agent, with greater potency in lysing platelet-rich clots and heightened specificity for fibrin may improve thrombolysis efficiency. However, the efficacy and safety of combining NAS minimally invasive puncture combined with TNK in reducing disability and mortality rates among patients with acute spontaneous deep intracerebral hemorrhage remain unknown.

Aim To evaluate the efficacy and safety of neuronavigation-assisted stereotactic MIPS combined with TNK thrombolysis (NAS-TNK)in reducing disability and mortality in patients with deep hypertensive intracerebral hemorrhage.

Design NAS-TNK is a randomized, open-label, outcome-blinded multicenter trial, involving 732 participants with acute basal ganglia or thalamic hemorrhage with a hematoma volume ranging from 20-50 mL. This study will evaluate the efficacy and safety of NAS minimally invasive puncture combined with TNK, administered every 24 hours at a dose of 0.009 mg per milliliter of hematoma volume, compared to participants receiving standard medical care. All patients will be followed up for 180 days.

Study outcomes The primary efficacy outcome is the proportion of subjects in the NAS-TNK group with a modified Rankin Scale (mRS) score between 0 and 3 at 180 days. The primary safety outcome is the all-cause death at 30-day.

The NAS-TNK study will help improve our understanding of the benefits of NAS minimally invasive puncture combined with TNK in patients with acute spontaneous deep intracerebral hemorrhage. This ongoing research will provide Level I evidence to guide clinicians in managing acute intracerebral hemorrhage treatment options.

Read the detailed description

Every year, more than 5 million cases of brain hemorrhage are reported worldwide. Minimally invasive surgery (MIS) has been established as an effective approach for treating acute spontaneous intracerebral hemorrhage and has received endorsement from both international and national clinical guidelines. Randomized controlled trials, such as MISTIE II, MISTIE III, and ENRICH, have demonstrated that procedures involving minimally invasive puncture or endoscopic hematoma evacuation significantly lower mortality rates among patients suffering from intracerebral hemorrhage. Data from these studies indicate that the mortality rate in the minimally invasive treatment groups has decreased from 18% to 26% down to approximately 9% to 19%. Additionally, the 2022 guidelines published by the American Heart Association and the American Stroke Association recommend these minimally invasive techniques as the preferred surgical intervention for patients with hematoma volumes exceeding 20 to 30 milliliters.

Minimally invasive puncture surgery (MIPS) combined with thrombolysis is particularly favored for its simplicity and broad applicability. This technique effectively aids in the evacuation of hematomas and alleviates pressure in cases of deep acute spontaneous intracerebral hemorrhages, all while minimizing the risk of iatrogenic injury and maximizing the protection of neural tissue. Although MIPS has shown promising outcomes in reducing procedure-related trauma, the long-term effectiveness of this method in preventing neurological deficits remains a subject of ongoing debate. Recent findings from the MISTIE III trial shed light on this issue. In this trial, the MISTIE group exhibited a mortality rate of 15% at 180 days, a significant reduction compared to the 23% observed in the standard care group (p=0.033). Furthermore, at 365 days, 45% of patients treated with MIPS achieved a modified Rankin Scale (mRS) score of 0 to 3, indicating favorable functional outcomes, compared to 41% in the standard medical care group, with no statistically significant difference observed between the two groups.

Nonetheless, subgroup analyses from the MISTIE III trial indicated that patients who underwent surgical intervention and achieved a hematoma reduction to less than 15 mL experienced significantly improved functional outcomes compared to those who received conservative treatment. This suggests that, in clinically stable patients, more aggressive and rapid removal of intracerebral hematomas may effectively lower the risk of mortality and enhance functional outcomes. Therefore, conducting trials that focus on rapid and extensive removal of hematoma volumes combined with MIPS would be beneficial in achieving better functional results.

The precise placement of the catheter tip within the hematoma is critical for the efficient and rapid evacuation of intracerebral hematoma. The thrombolytic agent delivered from the catheter tip relies on gravity to infiltrate and interact with the clot, thereby facilitating its dissolution. Simultaneously, the liquefied hematoma fluid is drained through the catheter tip. Neuronavigation-assisted stereotactic (NAS) technology can significantly enhance the accuracy of catheter tip placement, thereby reducing the risk of iatrogenic injuries and complications.

Tenecteplase (TNK), a third-generation thrombolytic agent derived from alteplase (rt-PA), offers several advantages over its predecessor. Its extended half-life allows for rapid administration via bolus infusion, providing logistical benefits compared to rt-PA. Additionally, TNK demonstrates increased resistance to inactivation by plasminogen activator inhibitor-1, resulting in a greater potency for lysing platelet-rich clots. Its heightened specificity for fibrin may also contribute to a reduction in hemorrhagic complications, especially those associated with systemic bleeding. These benefits have been evidenced in studies focused on conditions such as myocardial infarction and acute ischemic stroke. TNK has also shown effective thrombolytic effects, aiding in the dissolution of clots and promoting hematoma clearance. However, the efficacy and safety of combining NAS-assisted minimally invasive puncture with TNK (NAS-TNK) to reduce disability and mortality rates in patients with acute spontaneous deep intracerebral hemorrhage remain uncertain.

The NAS-TNK trial is designed to explore the impact of precise, rapid, and efficient clearance of hematoma volumes on the improvement of neurological function in patients. This multicenter, randomized, outcome-blinded study will evaluate the efficacy and safety of neuronavigation-assisted stereotactic MIPS combined with TNK thrombolysis in reducing disability and mortality rates in patients suffering from deep hypertensive intracerebral hemorrhage. This paper presents the design of the NAS-TNK trial and outlines its protocol in detail.

03

Conditions studied

  • Deep Intracerebral Hemorrhage (ICH)

Browse trials for

Keywords

  • Tenecteplase
  • Neuronavigation-assisted Stereotactic
  • Deep intracerebral hemorrhage
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years and \<80 years.
  2. Symptoms must have manifested within 24 hours prior to the diagnostic CT (dCT) scan. Cases with an indeterminate onset time are excluded. For patients who present symptoms upon sleeping, the last known time they were well should be used.
  3. Acute spontaneous deep intracerebral hemorrhage (ICH) occurring in the basal ganglia or thalamus, with a volume between 20-50 mL as measured by ABC/2 method with radiographic imaging (CT, etc.).
  4. Glasgow Coma Scale (GCS) score of 5-14.
  5. Stability CT scan done at least 6 hours after diagnostic CT showing clot stability (growth\<5 mL as measured by ABC/2 method).
  6. Randomization should occur within 6 to 24 hours after the diagnostic CT.
  7. Systolic blood pressure (SBP) less than 180 mmHg maintained for a duration of six hours, documented proximate to the randomization time point.
  8. Historical Rankin score of 0 or 1.

Exclusion criteria

Exclusion Criteria:

  1. Lobar or subtentorial hemorrhage, including posterior fossa hemorrhage and cerebellar hemorrhage.
  2. Stability CT scan done at least 6 hours after diagnostic CT showing clot instability (growth ≥5 mL as measured by ABC/2 method).
  3. Intraventricular hemorrhage necessitating intervention to address mass effect or midline shift attributable to trapped ventricle syndrome secondary to intraventricular hemorrhage (IVH)-related casting.
  4. Hemorrhage attributable to other cerebrovascular pathologies, including but not limited to ruptured aneurysm, arteriovenous malformation (AVM), vascular anomalies, moyamoya disease, hemorrhagic transformation of an ischemic infarct, or recurrence of a recent hemorrhage within the past year, as diagnosed through radiographic imaging.
  5. Patients presenting with an unstable intracranial mass or progressive intracranial compartment syndrome.
  6. Thalamic hemorrhages exhibiting evident extension into the midbrain, accompanied by oculomotor nerve palsy or pupils that are dilated and non-reactive. Other supranuclear gaze abnormalities do not constitute exclusion criteria.
  7. Irreversible impairment of brainstem function, characterized by bilateral fixed and dilated pupils, extensor motor posturing, and a Glasgow Coma Scale (GCS) score of ≤ 4.
  8. Indications for craniotomy in patients include: 1) progressive impairment of consciousness; 2) presence of brain herniation, with signs related to cerebellar tonsil herniation or temporal lobe gyrus herniation; 3) hematoma located within 1 cm of the cortical surface.
  9. CT evidence suggesting a high risk of rebleeding, such as spot sign.
  10. count \<100,000/mL; >1.4.
  11. Any irreversible coagulation disorders (e.g., hemophilia, von Willebrand disease, use of anticoagulants such as warfarin) or known clotting disorders (e.g., hypercoagulable states).
  12. Inability to maintain INR ≤1.4 using short-acting and long-acting procoagulants (e.g., recombinant human coagulation factor VIIa, fresh frozen plasma, vitamin K, etc.).
  13. Subjects necessitating long-term anticoagulation therapy are excluded from participation. Reversal of anticoagulation is permissible for medically stable patients who can feasibly tolerate the short-term risks associated with reversal. Patients must not require Coumadin (warfarin) or other anticoagulants during the initial 30-day period.
  14. Prior to the onset of symptoms, anticoagulants such as dabigatran, apixaban, or rivaroxaban, as well as treatments like tirofiban, ticagrelor, cilostazol, or clopidogrel, were used.
  15. Internal bleeding involving the retroperitoneal, gastrointestinal, or genitourinary system, or respiratory tract bleeding.
  16. Superficial or surface bleeding, observed mainly at vascular puncture and access sites (e.g., venous cutdowns, arterial punctures, etc.) or site of recent surgical intervention.
  17. Positive urine or serum pregnancy test in pre-menopausal female subjects without a documented history of surgical sterilization.
  18. Allergy/sensitivity to TNK.
  19. Prior enrollment in the study.
  20. Engagement in a concurrent interventional clinical investigation or trial. Patients enrolled in observational, natural history, or epidemiological studies that do not involve any form of intervention remain eligible.
  21. Not expected to survive until the day 180 visit due to co-morbidities, or having DNR/DNI status (Do-Not-Resuscitate and Do-Not-Intubate) prior to randomization.
  22. The presence of any concurrent serious illness that could confound outcome assessments, including but not limited to hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, immunologic, or hematologic disorders.
  23. Patients with mechanical heart valves are excluded. The presence of bioprosthetic valve(s) is permissible.
  24. Known risk for embolization, including history of left heart thrombus, mitral stenosis with atrial fibrillation, acute pericarditis, or subacute bacterial endocarditis. Atrial fibrillation without mitral stenosis is permitted.
  25. Any other condition that, in the investigator's judgment, would present a significant risk to the subject if the therapy were to be initiated.
  26. Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
  27. Patients deemed by the investigator to have unstable conditions that may benefit from other treatments.
  28. Patients requesting conservative treatment or standard craniotomy microsurgery treatment.
  29. The subject or their legal guardian/representative demonstrates an inability or lack of willingness to provide written .
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
732 participants (estimated)

Study arms

  • Sham comparator
    Standard medical treatment group

    The standard medical treatment for this group of patients will be provided according to the optimal care standards outlined by the American Heart Association (AHA) for the management of intracerebral hemorrhage.

    Drug: Standard medical treatment

  • Experimental
    NAS-TNK group

    This intervention involves neuronavigation-assisted stereotactic (NAS) minimally invasive puncture combined with tenecteplase (TNK). NAS minimally invasive puncture enhances catheter placement precision, reducing complications and improving hematoma evacuation and neurological outcomes. TNK, a third-generation thrombolytic, offers advantages over alteplase (rt-PA) , including a longer half-life for rapid bolus administration and effective thrombolytic effects to dissolve clots and promote hematoma clearance.

    Procedure: Neuronavigation-assisted Stereotactic Minimally Invasive Puncture Combined with Tenecteplase

Interventions

  • ProcedureNeuronavigation-assisted Stereotactic Minimally Invasive Puncture Combined with Tenecteplase

    Neuronavigation-assisted stereotactic minimally invasive puncture will enhances catheter placement precision, reducing complications and improving hematoma evacuation and neurological outcomes. TNK, a third-generation thrombolytic will offers advantages over alteplase (rt-PA), including a longer half-life for rapid bolus administration and effective thrombolytic effects to dissolve clots and promote hematoma clearance.

  • DrugStandard medical treatment

    The standard medical treatment for this group of patients will be provided according to the optimal care standards defined by the American Heart Association (AHA) guidelines for intracerebral hemorrhage management

06

What researchers measure

Primary outcomes

  1. Modified Rankin Scale (mRS) score of 0-3 at 180 days.

    The primary efficacy outcome is the proportion of patients achieving a favorable functional outcome, defined as a modified Rankin Scale (mRS) score of 0-3 at 180 days.

    Time frame: 180 ±14 days

Secondary outcomes

  1. Dichotomized eGOS (extended Glasgow Outcome Scale) score at 180 days: 4-8 (good) vs. 1-3(poor)

    Dichotomized eGOS (extended Glasgow Outcome Scale) score at 180 days: 4-8 (good) vs. 1-3 (poor). The eGOS is scored as: 1=Death, 2=Vegetative state, 3=Lower severe disability, 4=Upper severe disability, 5=Lower moderate disability, 6=Upper moderate disability, 7=Lower good recovery, 8=Upper good recovery.

    Time frame: 180 ± 14 days

  2. All-cause death at 180 days

    All-cause death at 180 days

    Time frame: 180 ± 14 days

  3. Dichotomized, modified Rankin Scale (mRS) Score 0-3 vs. 4-6 at 90 days.

    Proportion of patients with mRS of 0-3 (good functional status) at 90 days. The mRS is scored from: 0=No symptoms at all, 1=No significant disability, 2=Slight disability, 3=Moderate disability, 4=Moderately severe disability, 5=Severe disability and 6=death. Dichotomized scores are: 0-3=No symptoms to moderate disability requiring some assistance; 4-6=Moderately severe disability requiring complete assistance to death.

    Time frame: 90 ± 7 days

  4. Dichotomized graded modified Rankin Scale (mRS) score at 180 days : 0-2 vs. 3-6.

    Dichotomized graded modified Rankin Scale (mRS) score at 180 days post-hemorrhage: 0-2 vs. 3-6. The mRS is scored from: 0=No symptoms at all, 1=No significant disability, 2=Slight disability, 3=Moderate disability, 4=Moderately severe disability, 5=Severe disability and 6=death. Dichotomized scores are: 0-2=No symptoms to slight disability; 3-6=Moderate disability requiring some assistance to death.

    Time frame: 180 ± 14 days

  5. Ordinal graded modified Rankin Scale (mRS) score (0-6) at 180 days.

    Ordinal graded modified Rankin Scale (mRS) score (0-6) at 180 days. The mRS is scored from: 0=No symptoms at all, 1=No significant disability, 2=Slight disability, 3=Moderate disability, 4=Moderately severe disability, 5=Severe disability and 6=death.

    Time frame: 180 ± 14 days

  6. Barthel Index (BI) assessment at 180 days.

    Barthel Index assessment at 180 days. The Barthel Index (BI) assesses ten functional tasks of daily living, and each task provides a measure for level of independence. Scores range from 0 and 100, with a higher score indicating greater independence.

    Time frame: 180 ±14 days.

  7. Extended Glasgow Outcome (eGOS) assessment at 180 days.

    Extended Glasgow Outcome (eGOS) assessment at 180 days. The extended Glasgow Outcome Scale (eGOS) is a global scale for functional outcome with eight categories: 1 - Death, 2 - Vegetative State, 3 - Lower Severe Disability, 4 - Upper Severe Disability, 5 - Lower Moderate Disability, 6 - Upper Moderate Disability, 7 - Lower Good Recovery, 8 - Upper Good Recovery.

    Time frame: 180 ± 14 days

  8. The change of the National Institutes of Health Stroke Scale (NIHSS) at 5-7 days or discharge if earlier from baseline.

    The change of the National Institutes of Health Stroke Scale (NIHSS) at 5-7 days or discharge if earlier from baseline. Patients with a NIHSS score of less than 6 are considered to have a good recovery. The NIHSS is a 11-item scale that assesses language, motor function, sensory loss, consciousness, visual fields, extraocular movements, coordination, neglect, and speech. It is scored from 0 (no stroke symptoms) to 42 (severe stroke).

    Time frame: 5-7 days

  9. Safety/Mortality - All-cause death at 30 days

    All-cause death at 30 days

    Time frame: Within 30 days.

  10. Safety/Mortality - All-cause death at 7 days

    All-cause death at 7 days

    Time frame: Within 7 days

  11. Safety/Mortality - Symptomatic rebleeding within 6 days

    Symptomatic rebleeding events within 6 days post-randomization (defined as a persistent decrease in GCS motor score by more than 2 points, with a CT scan showing a new hematoma with a CT value greater than 72 HU and a volume exceeding 5 ml within the hematoma cavity and surrounding area compared to the prior scan).

    Time frame: Within 6 days

  12. Safety/Mortality - Intracranial bacterial infection within 30 days

    Intracranial bacterial infection within 30 days.

    Time frame: Within 30 days

  13. Safety/Mortality - Total Adverse Events (AEs) within 30 and 180 days

    Total Adverse Events (AEs) across all coded organ systems that occurred within 30 and 180 days.

    Time frame: Within 30 and 180 days

  14. Safety/Mortality - Total Serious Adverse Events (SAEs) within 30 and 180 days

    Total Serious Adverse Events (SAEs) within 30 and 180 days.

    Time frame: Within 30 and 180 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2025; primary completion for Mar 2027, 22 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2025
First posted
Mar 11, 2025
StartEst.
Apr 25, 2025
Primary completionEst.
Mar 1, 2027
CompletionEst.
Sep 1, 2027
Last update
Apr 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06868511
Responsible party
Dr. Yong Cao (Professor, Beijing Tiantan Hospital) — Principal investigator
First posted
Mar 11, 2025
Start date
Apr 25, 2025 (estimated)
Primary completion
Mar 1, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Apr 22, 2025

Study contacts

Yong Cao
Contact
caoyong@bjtth.org
+86 13601362306
Zhiyou Wu
Contact
786392247@qq.com
15880085161
Yong Cao
principal investigator · Beijing Tiantan Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion